Pneumolysin (PLY) (PLY)

Pneumolysin (PLY) is a 53-kDa protein and a primary virulence factor of Streptococcus pneumoniae, belonging to the family of cholesterol-dependent cytolysins (CDCs) [Source: UniProt P0C2J9]. Unlike most bacterial toxins, PLY is not secreted but is released into the host environment upon bacterial autolysis or through the action of certain antibiotics [Source: PubMed PMC3674452]. The protein functions by binding to cholesterol in host cell membranes, where it oligomerizes to form large transmembrane pores that cause direct cytolysis of respiratory epithelial cells, immune cells, and endothelial cells [Source: Nature Reviews Microbiology, 2009]. In addition to its pore-forming capabilities, PLY triggers the classical complement pathway and stimulates the production of pro-inflammatory cytokines, which can lead to severe tissue damage and systemic inflammation [Source: Journal of Infectious Diseases, 2011]. Given its critical role in the pathogenesis of pneumococcal disease, PLY is a significant therapeutic target; current strategies include the use of liposomal decoys like CAL02 to sequester the toxin and the development of non-toxic PLY derivatives for use in next-generation vaccines [Source: Lancet Infectious Diseases, 2019].

Other names

PneumolysinPLYThiol-activated cytolysinCholesterol-dependent cytolysin

Therapeutic strategies include toxin sequestration using liposomal decoys, competitive inhibition of cholesterol binding, and neutralization via monoclonal antibodies or vaccine-induced immunity.